Clinical Trials Browser

Phase 2 × Recruiting × BCG Vaccine × Clear all

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms